Abstract: The invention relates to a novel administration regime useful in the treatment of diseases or conditions where administration of insulin will be of benefit. In particular, the invention relates to a long-acting or ultra-long acting insulin for use in treating a disease or condition where administration of insulin will be of benefit, wherein the administration of said insulin includes or consists of one or more of the following steps: (a) obtaining a first data set of the subject, (b) obtaining a second data set of the subject, (c) obtaining a first data structure of the subject, and (d) obtaining a second data structure of the subject. When a determination is made that the at least first data structure, second data structure, first data set, and second data set collectively do contain the set of evaluation information, the device further includes providing the long-acting or ultra-long-acting insulin dose guidance recommendation.

Abstract: Techniques for determining therapy scores for at least two of an anti-PD1 therapy, an anti-CTLA4 therapy, an IL-2 therapy, an IFN alpha therapy, an anti-cancer vaccine therapy, an anti-angiogenic therapy, and an anti-CD20 therapy. The techniques include determining, using sequencing data for the subject and information indicating distribution of biomarker values across one or more reference populations, a first set of normalized biomarker scores for a first set of biomarkers associated with a first therapy; and a second set of normalized biomarker scores for a second set of biomarkers associated with a second therapy; providing the first set of normalized biomarker scores as input to a statistical model to obtain a first therapy score for the first therapy; and providing the second set of normalized biomarker scores as input to the statistical model to obtain a second therapy score for the second therapy.

Abstract: Techniques for generating therapy biomarker scores and visualizing same. The techniques include determining, using a patient's sequence data and distributions of biomarker values across one or more reference populations, a first set of normalized scores for a first set of biomarkers associated with a first therapy, and a second set of normalized scores for a second set of biomarkers associated with a second therapy, generating a graphical user interface (GUI) including a first portion associated with the first therapy and having at least one visual characteristic determined based on a normalized score of the respective biomarker in the first set of normalized scores; and a second portion associated with a second therapy and having at least one visual characteristic determined based on a normalized score of the respective biomarker in the second set of normalized scores; and displaying the generated GUI.

Abstract: During analyte analysis, errors may be introduced into an analysis by both the biosensor system used to perform the analysis and by errors in the output signal measured by the measurement device of the biosensor. For a reference sample, system error may be determined through the determination of relative error. However, during an analysis of a test sample with the measurement device of the biosensor system, true relative error cannot be known. A pseudo-reference concentration determined during the analysis may be used as a substitute for true relative error. The present invention introduces the determination of a pseudo-reference concentration determined during the analysis as a substitute for the true relative error and uses an anchor parameter to compensate for the system error in the analysis-determined pseudo-reference concentration.

Abstract: A system operating in a plurality of modes to provide an integrated analysis of molecular data, imaging data, and clinical data associated with a patient includes a multi-scale model, a molecular model, and a linking component. The multi-scale model is configured to generate one or more estimated multi-scale parameters based on the clinical data and the imaging data when the system operates in a first mode, and generate a model of organ functionality based on one or more inferred multi-scale parameters when the system operates in a second mode. The molecular model is configured to generate one or more first molecular findings based on a molecular network analysis of the molecular data, wherein the molecular model is constrained by the estimated parameters when the system operates in the first mode.

Abstract: Certain aspects of this disclosure relate to a screening method. In general terms, the screening assay comprises contacting test cells with a test compound to provide contacted test cells, obtaining values for a plurality of cytological attributes of the contacted test cells, and scoring the cells using the values to provide a likelihood score for at least one of a plurality of classifiers, where the plurality of classifiers are defined using values for cytological attributes obtained from cells that have been contacted with compounds of known mode of action.

Abstract: A method for subject-specific assessment of neurological disorders, the method includes receiving 3D image data representative of a subject's brain and identifying subject-specific anatomical structures in the 3D image data. A subject-specific model for electrical dynamics is created based on the 3D image data and the subject-specific anatomical structures and one or more functional indicators of neurological disorder are computed using the subject-specific model for electrical dynamics.

Abstract: A method and a device for identifying a single molecule, a method and a device for counting a single molecule and a system for processing a single molecule are provided.

Abstract: Systems, platforms, methods and media for providing genomic services are disclosed. In one example, a genomic services platform comprises a network interface through which are received genomic sequence reads derived from a biological sample obtained from a user. The platform also includes a bioinformatics processing pipeline including a read alignment module configured to generate observed sequence data by aligning the sequence reads relative to a reference sequence, a variant calling module operative to identify observed variants in the observed sequence data, and a variant refinement module for producing genotype data including a set of refined variants associated with the user. A variant imputation module produces a set of imputed variants associated with the user, and is configured to receive, as input, at least some of the genotype data and separate the genotype data into high-quality and low-quality genotypes based on a genotype quality.

Abstract: A classification of a level of cancer in an organism is determined by analyzing a biological sample of the organism. The biological sample comprises clinically-relevant DNA and other DNA. At least some of the DNA is cell-free in the biological sample. An amount of a first set of DNA fragments from the biological sample corresponding to each of a plurality of sizes is measured. A first value of a first parameter is calculated based on the amounts of DNA fragments at the plurality of sizes. The first value is compared to a reference value. A classification of a level of cancer in the organism is determined based on the comparison.

Abstract: A method of storing information using monomers such as nucleotides is provided including converting a format of information into a plurality of bit sequences of a bit stream with each having a corresponding bit barcode, converting the plurality of bit sequences to a plurality of corresponding oligonucleotide sequences using one bit per base encoding, synthesizing the plurality of corresponding oligonucleotide sequences on a substrate having a plurality of reaction locations, and storing the synthesized plurality of corresponding oligonucleotide sequences.

Abstract: A computer implemented system and method facilitates a cycle of generation, sharing, and refinement of volumes related to stimulation of anatomical tissue, such as brain or spinal cord stimulation. Such volumes can include target stimulation volumes, side effect volumes, and volumes of estimated activation. A computer system and method also facilitates analysis of groups of volumes, including analysis of differences and/or commonalities between different groups of volumes.

Abstract: An approach is provided for processing various sensor data and determining various characteristics associated with a user. A data collection module may process and/or facilitate a processing of sensor data for determining one or more distance measurements between at least one body part of a user and a device. The data collection module may determine one or more biometrical characteristics associated with the user based, at least in part, on the one or more distance measurements.

Abstract: A computer implemented system and method facilitates a cycle of generation, sharing, and refinement of volumes related to stimulation of anatomical tissue, such as brain or spinal cord stimulation. Such volumes can include target stimulation volumes, side effect volumes, and volumes of estimated activation. A computer system and method also facilitates analysis of groups of volumes, including analysis of differences and/or commonalities between different groups of volumes.

Abstract: In a vascular data generation apparatus, a processor generates first vascular data based on anatomical statistics data about vessels of an organ. This first vascular data has a tree structure representing a vascular network in the organ. The processor further generates second vascular data representing a plurality of vessels that connect a plurality of nodes in a geometric model of the organ with the vascular network represented by the first vascular data.

Abstract: A label-free imaging method to monitor stem cell metabolism discriminates different states of stem cell as they differentiate in a living tissues. We use intrinsic fluorescence biomarkers and the phasor approach to Fluorescence Lifetime Imaging Microscopy (FLIM). We identify and map intrinsic fluorophores such as collagen, retinol, retinoic acid, flavins, nicotinamide adenine dinucleotide (NADH) and porphyrin. We measure the phasor values of germ cells in C. Elegans germ line. Their metabolic fingerprint cluster according to their differentiation state, reflecting changes in FAD concentration and NADH binding during the differentiation pathway. The phasor approach to lifetime imaging provides a label-free, fit-free and sensitive method to identify different metabolic state of cells during differentiation, to sense small changes in the redox state of cells and may identify symmetric and asymmetric divisions and predict cell fate.

Abstract: The invention provides methods and reagents for diagnosing prostate cancer that are based on the detection of biomarkers in the circulating nucleic acids from a patient to be evaluated.

Abstract: Methods, systems, and apparatus are provided for determining whether a nucleic acid sequence imbalance exists within a biological sample. One or more cutoff values for determining an imbalance of, for example, the ratio of the two sequences (or sets of sequences) are chosen. The cutoff value may be determined based at least in part on the percentage of fetal DNA in a sample, such as maternal plasma, containing a background of maternal nucleic acid sequences. The percentage of fetal DNA can be calculated from the same or different data used to determine the cutoff value, and can use a locus where the mother is homozygous and the fetus is heterozygous. The cutoff value may be determined using many different types of methods, such as sequential probability ratio testing (SPRT).

Abstract: There is provided a canceration information providing method which can detect the possibility of cancer in the initial stage with high accuracy. The canceration information providing method for providing information pertaining to canceration of cells includes: acquiring measurement data including first data pertaining to size of a cell nucleus and second data pertaining to size of a cytoplasm for each cell contained in a measurement sample which includes cells collected from epithelial tissue; extracting the measurement data of cells to be analyzed, which are at least some of the cells located toward the basal membrane side of the cells existing in the surface layer in the epithelial tissue, from the measurement data of a plurality of cells in the measurement sample based on the first data and the second data acquired for each cell; and analyzing the extracted measurement data and outputting the information pertaining to the canceration of cells.

Abstract: A central question in cancer therapy is how individual cells within a population of tumor cells respond to drugs designed to arrest their growth. However, the absolute growth of cells, their change in physical mass, whether cancerous or physiologic, is difficult to measure directly with traditional techniques. Embodiments of the invention provide live cell interferometry (LCI) for rapid, realtime quantification of cell mass in cells exposed to a changing environment. Overall, LCI provides a conceptual advance for assessing cell populations to identify, monitor, and measure single cell responses, such as to therapeutic drugs.